Shares of Vertex (NASDAQ: VRTX) skyrocketed today, on very exciting news coming from a phase 2 trial of one of the company's cystic fibrosis drugs. Is Vertex the next big biotech that investors need to be a part of? In this video, Motley Fool health-care analyst David Williamson talks about the phase 2 results, and why investors should stand up and pay attention, and tells us where the company could go in 2013.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.